Alaunos Therapeutics Stock Performance
| TCRT Stock | USD 2.63 0.29 12.39% |
On a scale of 0 to 100, Alaunos Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 1.85, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alaunos Therapeutics will likely underperform. Please check Alaunos Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Alaunos Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Alaunos Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Alaunos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 12.39 | Five Day Return (0.75) | Year To Date Return (19.82) | Ten Year Return (99.64) | All Time Return (99.89) |
Last Split Factor 1:10 | Last Split Date 2024-07-18 |
1 | Why Alaunos Therapeutics Inc. stock could outperform in 2025 - Dollar Strength Long-Term Growth Portfolio Plans - newser.com | 11/11/2025 |
2 | Ziopharm Q3 Earnings Snapshot | 11/14/2025 |
3 | Acquisition by Jerman Michael Allen of 4183 shares of Alaunos Therapeutics at 3.16 subject to Rule 16b-3 | 11/21/2025 |
4 | Acquisition by Jerman Michael Allen of 10000 shares of Alaunos Therapeutics at 3.4 subject to Rule 16b-3 | 11/28/2025 |
5 | Why Alaunos Therapeutics Inc. stock is seen as undervalued - July 2025 Closing Moves Low Risk High Reward Trade Ideas - ulpravda.ru | 12/19/2025 |
6 | Retail Surge Will Alaunos Therapeutics Inc stock maintain dividend yield - 2025 Dividend Review AI Forecasted Entry and Exit Points - moha.gov.vn | 01/05/2026 |
7 | Acquisition by Vieser Jaime of 58 shares of Alaunos Therapeutics at 2.89 subject to Rule 16b-3 | 01/12/2026 |
8 | Acquisition by Postma Robert W of 54492 shares of Alaunos Therapeutics at 1.73 subject to Rule 16b-3 | 01/27/2026 |
9 | Acquisition by Melinda Lackey of 370000 shares of Alaunos Therapeutics at 1.22 subject to Rule 16b-3 | 01/28/2026 |
10 | Acquisition by De Groot Eleanor of 350000 shares of Alaunos Therapeutics subject to Rule 16b-3 | 02/05/2026 |
Alaunos Therapeutics Relative Risk vs. Return Landscape
If you would invest 253.00 in Alaunos Therapeutics on November 10, 2025 and sell it today you would earn a total of 10.00 from holding Alaunos Therapeutics or generate 3.95% return on investment over 90 days. Alaunos Therapeutics is currently generating 0.2477% in daily expected returns and assumes 6.1428% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Alaunos, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alaunos Therapeutics Target Price Odds to finish over Current Price
The tendency of Alaunos Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.63 | 90 days | 2.63 | about 86.35 |
Based on a normal probability distribution, the odds of Alaunos Therapeutics to move above the current price in 90 days from now is about 86.35 (This Alaunos Therapeutics probability density function shows the probability of Alaunos Stock to fall within a particular range of prices over 90 days) .
Alaunos Therapeutics Price Density |
| Price |
Predictive Modules for Alaunos Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Alaunos Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Alaunos Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Alaunos Therapeutics is not an exception. The market had few large corrections towards the Alaunos Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Alaunos Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Alaunos Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 1.85 | |
σ | Overall volatility | 0.52 | |
Ir | Information ratio | 0.01 |
Alaunos Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Alaunos Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Alaunos Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Alaunos Therapeutics had very high historical volatility over the last 90 days | |
| Alaunos Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 10 K. Net Loss for the year was (4.68 M) with loss before overhead, payroll, taxes, and interest of (910 K). | |
| Alaunos Therapeutics currently holds about 60.01 M in cash with (4.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. | |
| Alaunos Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by De Groot Eleanor of 350000 shares of Alaunos Therapeutics subject to Rule 16b-3 |
Alaunos Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Alaunos Stock often depends not only on the future outlook of the current and potential Alaunos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alaunos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.6 M | |
| Cash And Short Term Investments | 1.1 M |
Alaunos Therapeutics Fundamentals Growth
Alaunos Stock prices reflect investors' perceptions of the future prospects and financial health of Alaunos Therapeutics, and Alaunos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alaunos Stock performance.
| Return On Equity | -1.46 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (678.83) % | ||||
| Current Valuation | (58.38 K) | ||||
| Shares Outstanding | 2.23 M | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 978.28 X | ||||
| Revenue | 10 K | ||||
| Gross Profit | (910 K) | ||||
| EBITDA | (4.68 M) | ||||
| Net Income | (4.68 M) | ||||
| Cash And Equivalents | 60.01 M | ||||
| Cash Per Share | 0.28 X | ||||
| Total Debt | 692 K | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 2.29 X | ||||
| Book Value Per Share | 1.27 X | ||||
| Cash Flow From Operations | (4.97 M) | ||||
| Earnings Per Share | (2.30) X | ||||
| Market Capitalization | 5.87 M | ||||
| Total Asset | 2.75 M | ||||
| Retained Earnings | (920.45 M) | ||||
| Working Capital | 2.06 M | ||||
About Alaunos Therapeutics Performance
Assessing Alaunos Therapeutics' fundamental ratios provides investors with valuable insights into Alaunos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Alaunos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.53) | (1.60) | |
| Return On Capital Employed | (2.10) | (2.20) | |
| Return On Assets | (1.53) | (1.60) | |
| Return On Equity | (2.61) | (2.48) |
Things to note about Alaunos Therapeutics performance evaluation
Checking the ongoing alerts about Alaunos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alaunos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alaunos Therapeutics had very high historical volatility over the last 90 days | |
| Alaunos Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 10 K. Net Loss for the year was (4.68 M) with loss before overhead, payroll, taxes, and interest of (910 K). | |
| Alaunos Therapeutics currently holds about 60.01 M in cash with (4.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. | |
| Alaunos Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by De Groot Eleanor of 350000 shares of Alaunos Therapeutics subject to Rule 16b-3 |
- Analyzing Alaunos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alaunos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Alaunos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alaunos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alaunos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alaunos Therapeutics' stock. These opinions can provide insight into Alaunos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.